Table 1.
Baseline characteristics of primary breast cancer patients (n = 64) at day of first diagnosis.
| Total | CTX | CTX+VA | VA | p-value | |
|---|---|---|---|---|---|
| Number of patients, n (%) | 64 (100) | 25 (100) | 31 (100) | 8 (100) | |
| Age, years, median (IQR) | 54.8 (46.3-65.3) | 50.5 (44.0-52.0) | 56.9 (49.9-65.3) | 59.9 (51.0-76.2) | 0.155 |
| BMI, median (IQR) | 25.9 (22.7-28.0) | 26.3 (23.0-28.8) | 25.3 (22.2-28.2) | 26.8 (23.0-27.4) | 0.231 |
|
| |||||
| UICC stages, n (%) | |||||
| I | 24 (37.5) | 9 (36.0) | 13 (41.9) | 2 (25.0) | |
| II | 26 (40.6) | 10 (40.0) | 12 (38.7) | 4 (50.0) | 0.926 |
| III | 14 (21.9) | 6 (24.0) | 6 (19.4) | 2 (25.0) | |
|
| |||||
| Hormonal status, n (%) | |||||
| Pre-menopausal | 26 (40.6) | 15 (60.0) | 8 (25.8) | 3 (37.5) | |
| Peri-menopausal | 5 (7.8) | 4 (16.0) | 1 (3.2) | 0 (0) | 0.008∗ |
| Post-menopausal | 33 (51.6) | 6 (24.0) | 22 (71.0) | 5 (62.5) | |
|
| |||||
| Estrogen receptor positive | 41 (64.1) | 15 (60.0) | 19 (61.3) | 7 (87.5) | 0.334 |
| Progesteron receptor positive | 40 (62.5) | 16 (64.0) | 19 (61.3) | 5 (62.5) | 0.979 |
| HER 2 positive | 23 (35.9) | 7 (28.0) | 14 (45.2) | 2 (25.5) | 0.325 |
|
| |||||
| Interventions, n (%) | |||||
| CTX, n (%) | 56 (87.5) | 25 (100) | 31 (100) | 0 (0) | <0.001∗∗ |
| VA therapy, n (%) | 39 (60.9) | 0 (0) | 31 (100) | 8 (100) | <0.001∗∗ |
| Radiation, n (%) | 44 (68.8) | 19 (76) | 22 (88.0) | 3 (37.5) | 0.115 |
TNM staging according to the Union for International Cancer Control (UICC). n = number of patients and portion (%). CTX = chemotherapy; VA = Viscum album L. therapy; BMI: body mass index. The p-values of Pearson's chi-square analyses of the three groups were determined using R-statistics.